33649-73-9

Usage

InChI:InChI=1/C12H18O2/c1-11-3-8-2-9(4-11)6-12(5-8,7-11)10(13)14/h8-9H,2-7H2,1H3,(H,13,14)

Upstream product

• 64-18-6 formic acid 
• 768-91-2 1-methyl-adamantane 
• 101974-65-6 3-methyl-1-adamantanol nitrate 
• 702-81-8 3-methyl-1-adamantanol 
• 702-77-2 1-bromo-3-methyladamantane 
• 32789-29-0 exo-tetrahydrodicyclopentadiene 
• 702-80-7 3-Methyl-1-chloroadamantane 

Downstream Products

• 14670-95-2 5-methyl-3-bromoadamantane-1-carboxylic acid 
• 702-81-8 3-methyl-1-adamantanol 
• 14670-99-6 5-Amino-1-methyl-adamantan-carbonsaeure-(3) 
• 14575-01-0 methyl 3-bromo-1-adamantaneacetate 
• 14202-13-2 (3-methyladamantan-1-yl)acetic acid 
• 1687-34-9 1-ethyl-3-methyladamantane 

Relevant academic research and scientific papers

Synthesis and biological evaluation of memantine nitrates as a potential treatment for neurodegenerative diseases

A series of memantine nitrate derivatives, as dual functional compounds with neuroprotective and vasodilatory activity for neurodegenerative diseases, was designed and synthesized. These compounds combined the memantine skeleton and a nitrate moiety, and thus inhibited the N-methyl-d-aspartic acid receptor and released NO in the central nervous system. The biological evaluation results revealed that the new memantine nitrates were effective in protecting neurons against glutamate-induced injury in vitro. Moreover, memantine nitrates dilated aortic rings against phenylephrine-induced contraction. The structure-activity relationships of neuroprotection and vasodilation were both analyzed. In further studies, compound MN-05 significantly protected cortical neurons by inhibiting Ca2+ influx, reducing free radical production and maintaining the mitochondrial membrane potential. Further research on MN-05 is warranted.

AMINO ADAMANTANE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF

The invention relates to 1-amino adamantane derivatives and 3-amino adamantane-1-carboxylic acid derivatives, wherein the 5th and/or 7th position of the adamantane base frame can be substituted in any particular manner. The invention also relates to methods for the production of said inventive compounds, in addition to methods for linking the thus obtained monomer 3-amino adamantane-1-carboxylic acid derivatives in order to form oligomers. The inventive compounds are suitable for use as anti-viral active substances, artificial ion channels and for the therapy, diagnosis and prophylaxis of diseases, wherein a defect of the GA-BA-system occurs.

NITRATION OR CARBOXYLATION CATALYSTS

In the presence of an imide compound (e.g., N-hydroxyphthalimide) shown by the following formula (1): ???wherein R1and R2represent a hydrogen atom, a halogen atom, an alkyl group, an aryl group and a cycloalkyl group, and R1and R2may bond together to form a double bond, or an aromatic or non-aromatic ring, and Y is an O or OH, and n denotes 1 to 3;, a substrate is allowed to contact with at least one reactant selected from (i) a nitrogen oxide and (ii) a mixture of carbon monoxide and oxygen to be introduced with at least one functional group selected from a nitro group and a carboxyl group. The nitrogen oxide includes, for example, a compound represented by the formula NxOy(e.g., N2O3, NO2). The substrate includes, for example, a compound having a methine carbon atom (e.g., adamantane), a compound having a methyl group or a methylene group at an adjacent moiety of an aromatic ring. According to such reaction, the substrate can be efficiently nitrated or carboxylated even in a mild or moderate condition.